Skip to main content

Stryker Corporation (SYK) Stock Analysis

Falling Knife setup

Buy WaitModerate Confidence

Healthcare · Medical Devices

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait — supporting gate not met yet. Price is at or below entry $323.34 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risk: Concentration risk — Supplier: sole-source raw materials and services.

Stryker is a global medical technology company with two segments: MedSurg and Neurotechnology (62% of $25.1B 2025 net sales) and Orthopaedics (38%), selling surgical equipment, instruments, endoscopy, patient handling, neurovascular, and joint replacement products in ~61... Read more

$317.01+19.6% A.UpsideScore 5.6/10#15 of 40 Medical Devices
Entry $323.34(Support Atr Sticky)Stop $306.72Target $377.20(analyst − 10%)A.R:R 3.6:1
Analyst target$419.11+32.2%27 analysts
$377.20our TP
$317.01price
$419.11mean
$469

Wait — supporting gate not met yet. Price is at or below entry $323.34 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risk: Concentration risk — Supplier: sole-source raw materials and services. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Earnings in 0 days. Wait until post-earnings. Score 5.6/10, moderate confidence.

Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: moderate.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: sole-source raw materials and services

Key Metrics

P/E (TTM)37.5
P/E (Fwd)18.8
Mkt Cap$120.7B
EV/EBITDA19.1
Profit Mgn12.9%
ROE15.1%
Rev Growth11.4%
Beta0.93
Dividend1.12%
Rating analysts36

Quality Signals

Piotroski F9/9

Options Flow

P/C0.18bullish
IV45%normal
Max Pain$210-33.8% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSuppliersole-source raw materials and services
    10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA, MA slope -2.0%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
2.3
Growth Rank
5.3
Quality Rank
6.9
GatesMomentum 1.1<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 0d<=7dA.R:R 3.6 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
32 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $311.31Resistance $352.80

Price Targets

$307
$323
$377
A.Upside+19.0%
A.R:R3.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Earnings in 0 days - binary event risk
! Momentum score 1.1/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SYK stock a buy right now?

Wait — supporting gate not met yet. Price is at or below entry $323.34 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risk: Concentration risk — Supplier: sole-source raw materials and services. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Earnings in 0 days. Wait until post-earnings. Target $377.20 (+19.0%), stop $306.72 (−3.4%), Setup A.R:R 4.6:1. Score 5.6/10, moderate confidence.

What is the SYK stock price target?

Take-profit target: $377.20 (+19.6% upside). Target $377.20 (+19.0%), stop $306.72 (−3.4%), Setup A.R:R 4.6:1. Stop-loss: $306.72.

What are the risks of investing in SYK?

Concentration risk — Supplier: sole-source raw materials and services.

Is SYK overvalued or undervalued?

Stryker Corporation trades at a P/E of 37.5 (forward 18.8). TrendMatrix value score: 5.3/10. Verdict: Buy (Wait for Entry).

What do analysts say about SYK?

36 analysts cover SYK with a consensus score of 4.1/5. Average price target: $419.

What does Stryker Corporation do?Stryker is a global medical technology company with two segments: MedSurg and Neurotechnology (62% of $25.1B 2025 net...

Stryker is a global medical technology company with two segments: MedSurg and Neurotechnology (62% of $25.1B 2025 net sales) and Orthopaedics (38%), selling surgical equipment, instruments, endoscopy, patient handling, neurovascular, and joint replacement products in ~61 countries. Products marketed directly to doctors, hospitals, and healthcare facilities, with Mako robotic-arm technology as a key platform.

Related stocks: DXCM (DexCom, Inc.) · BSX (Boston Scientific Corporation) · PODD (Insulet Corporation) · SNN (Smith & Nephew SNATS, Inc.) · PHG (Koninklijke Philips N.V. NY Reg)